Next Article in Journal
Aquaculture Soft Coral Lobophytum crassum as a Producer of Anti-Proliferative Cembranoids
Next Article in Special Issue
A New Breviane Spiroditerpenoid from the Marine-Derived Fungus Penicillium sp. TJ403-1
Previous Article in Journal
Suppression of RANKL-Induced Osteoclastogenesis by the Metabolites from the Marine Fungus Aspergillus flocculosus Isolated from a Sponge Stylissa sp.
Previous Article in Special Issue
Cytotoxic and Antibacterial Compounds from the Coral-Derived Fungus Aspergillus tritici SP2-8-1
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 16
Issue 1
10.3390/md16010012
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Secondary Metabolites of Mangrove-Associated Strains of Talaromyces

by
Rosario Nicoletti
1,2,
Maria Michela Salvatore
3 and
Anna Andolfi
3,*
1
Council for Agricultural Research and Agricultural Economy Analysis, 00184 Rome, Italy
2
Department of Agriculture, University of Naples ‘Federico II’, 80055 Portici, Italy
3
Department of Chemical Sciences, University of Naples ‘Federico II’, 80125 Naples, Italy
*
Author to whom correspondence should be addressed.
Mar. Drugs 2018, 16(1), 12; https://doi.org/10.3390/md16010012
Submission received: 8 November 2017 / Revised: 24 December 2017 / Accepted: 28 December 2017 / Published: 6 January 2018
(This article belongs to the Special Issue Bioactive Compounds from Marine-Derived Aspergillus, Penicillium, Talaromyces and Trichoderma Species)
Versions Notes

Abstract

:
Boosted by the general aim of exploiting the biotechnological potential of the microbial component of biodiversity, research on the secondary metabolite production of endophytic fungi has remarkably increased in the past few decades. Novel compounds and bioactivities have resulted from this work, which has stimulated a more thorough consideration of various natural ecosystems as conducive contexts for the discovery of new drugs. Thriving at the frontier between land and sea, mangrove forests represent one of the most valuable areas in this respect. The present paper offers a review of the research on the characterization and biological activities of secondary metabolites from manglicolous strains of species belonging to the genus Talaromyces. Aspects concerning the opportunity for a more reliable identification of this biological material in the light of recent taxonomic revisions are also discussed.

1. Introduction

The establishment of the concept of ‘one fungus, one name’ in mycology [1] has stimulated reconsideration of the nomenclature of fungi, whose anamorphic stages were until recently grouped in the genus Penicillium, and included species renowned for being among the most prolific producers of bioactive secondary metabolites and a few blockbuster drugs [2,3,4]. In fact, a fundamental taxonomic revision has ultimately established that species with symmetrical biverticillate conidiophores, which were formerly ascribed to the Penicillium subgenus Biverticillium, are to be classified separately in the genus Talaromyces, and that Penicillium and Talaromyces belong to phylogenetic lineages that are distant enough to deserve ascription to different families [5,6]. Under the ecological viewpoint, recent reports are depicting a widespread endophytic occurrence of Talaromyces [7,8,9,10], which makes these fungi increasingly considered a source of interesting bioactive compounds.
After a few years, the above revision has not yet found full consideration. This is particularly true among researchers working in the field of drug discovery, who sometimes do not possess a robust mycological background. In fact, in a number of recent reports limiting identification to the genus level, the name Penicillium sp. is still inappropriately used for strains displaying the symmetrical biverticillate conidiophore condition. It is of course desirable that hasty investigators be more circumstantial in considering this fundamental step when reporting on their findings. Moreover, in contrast to the purpose of increasing accuracy, the adoption of identification procedures that are only based on DNA sequence homology has sometimes introduced additional approximation, considering that plenty of sequences referring to ‘Penicillium sp.’ have been deposited in GenBank, and are routinely used as a support for the incomplete classification of new strains. Pending the diffusion of more decisive identification protocols, a good portion of the work carried out so far in the field of the purification and characterization of secondary metabolites from Penicillium/Talaromyces strains awaits revision in order to attain a more conclusive taxonomic ascription of this biological material, and avoid possible confusion from unreliable information. In fact, data concerning the production of secondary metabolites can be quite informative for these fungi, particularly when they are indicative of the ability to synthesize some structural models that are only, or predominantly, found in Talaromyces [11,12].
Following a recent paper on bioactive compounds from Talaromyces strains obtained from other marine sources [3], this review examines literature concerning secondary metabolites produced by these fungi recovered in association with mangrove plants, including a number of reports adopting the generic denomination ‘Penicillium sp.’.

2. Mangrove Swamps: A Dynamic Frontier between Land and Sea

Spread along the coastlines at tropical and subtropical latitudes, mangrove forests are a biodiversity hotspot as well as a peculiar transition ecosystem, harboring organisms that are typical of either marine or terrestrial habitats. Considering their prevalently emerged bearing, mangrove plants cannot be considered real marine organisms to the same extent as seagrasses [3]. However, they play a key role in maintaining and building soil from the intertidal zone, and are morphologically and physiologically adapted to the particularly harsh environmental conditions deriving from a combination of extensive salinity, tide alternation, anaerobic clayey soil, high temperature, and moisture [13].
Mangrove plants host a great variety of endophytic and other associated fungi, a good part of which derives from the surrounding soil, marine, and freshwater contexts. Regardless of their true origin, which in most instances cannot be proven, these symbionts might contribute to their host’s adaptation in such a peculiar habitat [14]. According to the plant species, the environmental conditions, and other factors, a wide set of interactions are potentially established between endophytes and their hosts [15]. However, the most considered aspect is represented by the mutual effects on the production of secondary metabolites. Recent investigations have demonstrated that these secondary metabolites are regulated by complex biomolecular mechanisms, such as chromatin methylation [16], and are regarded as fundamental mediators of interspecific communication [17]. In applicative terms, this intriguing ecological scenario reflects a series of bioactive properties of a multitude of structurally diverse compounds that these fungi are able to synthesize, stimulating their consideration as one of the most promising sources for drug prospects [14,18,19,20,21,22].

3. The Occurrence of Talaromyces Species in Mangroves

In the last decade, literature concerning drug discovery has been substantially enriched by many reports dealing with the biosynthetic potential of mangrove-associated fungi. Also, there has been an increasing trend over the past few years in the finding of Talaromyces strains from this particular ecological context, which appears to be in evident connection with its quite recent spread in nomenclatural use following the formal separation from Penicillium. However, apart from two cases from South America, these reports all refer to locations in southeast Asia, particularly from the Chinese provinces of Fujian, Guangdong, and Guangxi, and Hainan Island (Table 1).
However, it is questionable whether some of these reports are actually replications. In fact, the strains YX1 and HZ-YX1 obtained from leaf samples of Kandelia obovata were claimed to have been collected in April 2012 at two locations in the Guangdong province situated over 400 km apart. Both strains were ascribed to the species T. amestolkiae based on rDNA-ITS sequence homology; nevertheless, the same GenBank accession code is indicated by the authors, which refers to Zhanjiang as the place of origin (hence strain YX1) [24,25]. Even more ambiguous is the case of strain 9EB of T. aculeatus, whose identification was again based on the homology of a 16S sequence of 576 bp deposited in GenBank (accession code: KT715695), which is actually referred to a strain of Penicillium sp. that had been given a different number (C08652) [23]. However, this sequence is identical to one from another strain (CY196, accession number: KP059103) identified as T. verruculosus, again submitted from Chinese researchers from Guangzhou. Finally, substantial perplexity arises for three strains labeled with the same number (FJ-1) despite a declared different origin, which are reported to have been identified through rDNA-ITS sequencing [33,34,35]. However, the GenBank code (DQ365947.1) provided for all of them actually corresponds to a previously deposited sequence from a strain of T. purpurogenus (HS-A82).

4. Structures and Properties of Secondary Metabolites from Manglicolous Talaromyces

Most of the strains mentioned in Table 1 were reported for the production/bioactive effects of secondary metabolites, which undoubtedly represent the major objective prompting research on endophytic fungi. The structure of these compounds was essentially elucidated by means of spectroscopic methods, such as two-dimensional (2D) NMR and mass spectrometry. In some cases, their absolute configuration was determined through a modified Mosher’s method or electronic circular dichroism (ECD) spectra, or the structures confirmed by means of single-crystal X-ray diffraction experiments. So far, 39 new compounds out of a total of 88 (Table 2) have resulted from the biochemical characterization of these strains. Aside from a few quite original structural models, most of them are strictly correlated to known products that have been previously reported from other strains of Talaromyces [2,3,11]. A lower number of compounds (22) already known from this genus have also been identified in manglicolous strains, indicating that research in this particular field has yielded a notable percentage of new products. However, it is not possible to infer whether these numbers subtend any specific biosynthetic abilities, considering that it is quite likely that a few novel products were not previously detected in strains of different origin by the simple reason that they had not been characterized yet.
The majority of these secondary metabolites have been evaluated for some kind of biological properties, particularly cytotoxic/antiproliferative activity against tumor cell lines, antimicrobial effects against bacterial and fungal strains, and immunosuppressive and enzyme inhibitory aptitudes. However, some interesting effects have been also described for many of the other 49 compounds previously reported from other biological sources, which have not been specifically considered in Table 2.
As a likely result of evolutionary pressure, genes encoding fungal secondary metabolites are known to be clustered, and their synthesis is known to occur through a few common schemes, such as the acetate, shikimate, and mevalonate pathways [42]. Nevertheless, the molecular structure of these compounds is very varied, even within a single genus such as Talaromyces, and a convenient discussion should be based on their grouping in different classes [43].
Depsidones are ester-like depsides, or cyclic ethers, which are related to the diphenyl ethers, and synthesized through the polymalonate pathway. Their structure is based on an 11H-dibenzo(b,e) [1,4] dioxepin-11-one ring system where bridging at the phenolic group in the p-position can result in increased antioxidant activity. The efficient antioxidant properties of depsidones may also derive from their incorporation into lipid microdomains [44]. Since antioxidant properties are in turn related to anti-inflammatory, antiproliferative, and antiviral activities, compounds from Talaromyces spp. belonging to this class, particularly the novel talaromyones A and B [39], should be better investigated with reference to these bioactive effects. Funicones and the related vermistatins probably represent the most typical class of secondary metabolites produced by Talaromyces spp., possessing several bioactive properties that make them renowned drug prospects [45]. Particularly, 3-O-methylfunicone has displayed notable antifungal, antitumor, and lipid-lowering properties that require more circumstantial investigations beyond academic research, for which a direct support by the pharmaceutical industry seems to be fundamental [46,47,48,49,50,51]. A few novel vermistatin derivatives obtained from a manglicolous strain of T. pinophilus have been characterized as α-glucosidase inhibitors [29].
In fungi, both anthraquinones and xanthones are reported to be synthesized through the cyclization of polyacetate units, in the latter case followed by oxidative cleavage of the central ring [52]. Well-known mycotoxins ascribed to these groups, such as emodin, skyrin, secalonic acid A, and norlichexanthone, have been also reported as secondary metabolites of a manglicolous Talaromyces strain [38]. The related benzophenones are represented by the new potent immunosuppressive product peniphenone and its methyl derivative [32]. Other phenolic metabolites are possibly synthesized following the shikimate pathway [53], such as two new biphenyl and phenylcyclopentenone derivatives that have been characterized for their α-glucosidase inhibitory effects [41].
Benzofurans, also known as coumarones, represent another important class of natural products, and a scaffold considered for the development of synthetic drugs [54]. This group includes two new compounds derived from strain YX1 of T. amestolkiae, which exhibit antibacterial activities [24]. Again known for a wide array of pharmacological properties, isocoumarins are coumarin isomers presenting an inverted lactone ring, most of which possess a 3-alkyl or a 3-phenyl moiety on a α-pyranone nucleus, and 8-oxygenation on the benzene ring. The discovery of novel natural isocoumarins is ongoing; a few hundreds of isocoumarins and dihydroisocoumarins are currently known from different sources [55]. Despite such a high diversity, the number of isocoumarins displaying a completely different substitution pattern is quite reduced, and most of the newly isolated products turn out to be derivatives of previously known structures. A good example is represented by a series of known and novel compounds by the above-mentioned strain YX1, which have been again characterized for their α-glucosidase inhibitory effects [24]. The talaroflavones, including the new antibacterial analogue 7-hydroxy-deoxytalaroflavone [33], are also ascribed to this class.
Azaphilones are a typical class of fungal red or purple pigments with pyrone–quinone structures containing a highly oxygenated bicyclic core and a chiral quaternary center, whose use as colorants has been proposed in several fields, including the food industry [56]. These compounds exhibit a wide range of bioactivities, deriving from antimicrobial, antiviral, antioxidant, cytotoxic, nematicidal, and anti-inflammatory properties [57,58]. New members of this family are represented by the antibacterial/cytotoxic product 7-epiaustdiol and its methyl derivative [38], and the pinazaphilones, which have been characterized as α-glucosidase inhibitors [41]. Another red pigment, glauconic acid, is probably the oldest product mentioned in this review. In fact, this nonadride compound has been known since 1931 [59], mainly from studies concerning its biosynthetic pathway, which indicate that it derives through several steps involving substitutions in citric acid and dimerization of a C9 anhydride unit [60], or from succinate [61]. However, no detailed investigation of its bioactivity seems to have been accomplished so far. α-glucosidase inhibitory activity also characterizes bacillosporins (bacillisporins) A and B, two known antibacterial oligophenalenone dimers reported together with a new chromone from a strain of T. aculeatus [23]. Additional novel polyketides from manglicolous Talaromyces strains are represented by leptosphaerone C, a cytotoxic cyclohexenone derivative [32], and the flavonoid (2R,3S)-pinobanksin-3-cinnamate, displaying interesting neuroprotective effects [35].
Although alkaloids are widespread secondary metabolites of endophytic fungi [62], only two representatives of this class have been reported from mangrove-associated Talaromyces strains. Particularly, ZG-1494α is a pyrrolidinone derivative that has been reported as an inhibitor of the platelet-activating factor acetyltransferase [63], while talaramide A is a new compound presenting an unusual oxidized tricyclic system, which has been characterized for its antimycobacterial properties deriving from PknG kinase inhibitory effects [25].
Finally, the terpenes also appear to be quite infrequent from this particular microbial source. They include the sesquiterpene amino acid-alcohol ester purpuride [26], and a few novel cytotoxic-antiproliferative products, namely 15-hydroxy-6α,12-epoxy-7β,10αH,11βH-spiroax-4-ene-12-one [34], 15-α-hydroxy-(22E,24R)-ergosta-3,5,8(14),22-tetraen-7-one [35], and the talaperoxide series [27].

5. Conclusions

The availability of increasingly refined laboratory equipment, and the ability to access previously hindered sources for the isolation of novel fungal strains has stimulated a huge amount of research activity in view of identifying new bioactive compounds and drugs. Moreover, novel accurate screening strategies and procedures have been introduced for a targeted selection in view of reducing the misuse of resources and ensuing replication through finding known compounds [64,65,66,67]. With an increasing rate of recovery from both terrestrial and marine environmental contexts, and a wide range of ecological interactions with other organisms, Talaromyces strains are among the most promising ‘biofactories’ that can further enlarge the current panorama of bioactive products available for exploitation by the pharmaceutical industry. Considering the relatively reduced extension of the areas covered by such investigations so far, this remarkable potential deserves to be more thoroughly appreciated, particularly by spreading the search for new strains all over the manglicolous regions that have not yet been considered.

Author Contributions

R.N. and A.A. conceived and organized the manuscript, and wrote the text; M.M.S. gathered data from the literature and prepared Table 2.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hawksworth, D.L.; Crous, P.W.; Redhead, S.A.; Reynolds, D.R.; Samson, R.A.; Seifert, K.A.; Taylor, J.W.; Wingfield, M.J.; Abaci, O.; Aime, C.; et al. The Amsterdam declaration on fungal nomenclature. IMA Fungus 2011, 2, 105–112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Frisvad, J.C. Taxonomy, chemodiversity, and chemoconsistency of Aspergillus, Penicillium, and Talaromyces species. Front. Microbiol. 2015, 5, 773. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Nicoletti, R.; Trincone, A. Bioactive compounds produced by strains of Penicillium and Talaromyces of marine origin. Mar. Drugs 2016, 14, 37. [Google Scholar] [CrossRef] [PubMed]
  4. Koul, M.; Singh, S. Penicillium spp.: Prolific producer for harnessing cytotoxic secondary metabolites. Anti-Cancer Drugs 2017, 28, 11–30. [Google Scholar] [CrossRef] [PubMed]
  5. Houbraken, J.; Samson, R.A. Phylogeny of Penicillium and the segregation of Trichocomaceae into three families. Stud. Mycol. 2011, 70, 1–51. [Google Scholar] [CrossRef] [PubMed]
  6. Yilmaz, N.; Visagie, C.M.; Houbraken, J.; Frisvad, J.C.; Samson, R.A. Polyphasic taxonomy of the genus Talaromyces. Stud. Mycol. 2014, 78, 175–341. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Li, L.Q.; Yang, Y.G.; Zeng, Y.; Zou, C.; Zhao, P.J. A new azaphilone, kasanosin C, from an endophytic Talaromyces sp. T1BF. Molecules 2010, 15, 3993–3997. [Google Scholar] [CrossRef] [PubMed]
  8. Bara, R.; Aly, A.H.; Pretsch, A.; Wray, V.; Wang, B.; Proksch, P.; Debbab, A. Antibiotically active metabolites from Talaromyces wortmannii, an endophyte of Aloe vera. J. Antibiot. 2013, 66, 491–493. [Google Scholar] [CrossRef] [PubMed]
  9. Palem, P.P.; Kuriakose, G.C.; Jayabaskaran, C. An endophytic fungus, Talaromyces radicus, isolated from Catharanthus roseus, produces vincristine and vinblastine, which induce apoptotic cell death. PLoS ONE 2015, 10, e0144476. [Google Scholar] [CrossRef] [PubMed]
  10. Vinale, F.; Nicoletti, R.; Lacatena, F.; Marra, R.; Sacco, A.; Lombardi, N.; d’Errico, G.; Digilio, M.C.; Lorito, M.; Woo, S.L. Secondary metabolites from the endophytic fungus Talaromyces pinophilus. Nat. Prod. Res. 2017, 31, 1778–1785. [Google Scholar] [CrossRef] [PubMed]
  11. Frisvad, J.C.; Filtenborg, O.; Samson, R.A.; Stolk, A.C. Chemotaxonomy of the genus Talaromyces. Antonie van Leeuwenhoek 1990, 57, 179–189. [Google Scholar] [CrossRef] [PubMed]
  12. Zhai, M.M.; Li, J.; Jiang, C.X.; Shi, Y.P.; Di, D.L.; Crews, P.; Wu, Q.X. The bioactive secondary metabolites from Talaromyces species. Nat. Prod. Bioprospect. 2016, 6, 1–24. [Google Scholar] [CrossRef] [PubMed]
  13. Lee, S.Y.; Primavera, J.H.; Dahdouh-Guebas, F.; McKee, K.; Bosire, J.O.; Cannicci, S.; Diele, K.; Fromard, F.; Koedam, N.; Marchand, C.; et al. Ecological role and services of tropical mangrove ecosystems: A reassessment. Glob. Ecol. Biogeogr. 2014, 23, 726–743. [Google Scholar] [CrossRef] [Green Version]
  14. Debbab, A.; Aly, A.H.; Proksch, P. Mangrove derived fungal endophytes—A chemical and biological perception. Fungal Divers. 2013, 61, 1–27. [Google Scholar] [CrossRef]
  15. Wani, Z.A.; Ashraf, N.; Mohiuddin, T. Plant-endophyte symbiosis, an ecological perspective. Appl. Microbiol. Biotechnol. 2015, 99, 2955–2965. [Google Scholar] [CrossRef] [PubMed]
  16. Chujo, T.; Scott, B. Histone H3K9 and H3K27 methylation regulates fungal alkaloid biosynthesis in a fungal endophyte–plant symbiosis. Mol. Microbiol. 2014, 92, 413–434. [Google Scholar] [CrossRef] [PubMed]
  17. Netzker, T.; Fischer, J.; Weber, J.; Mattern, D.J.; König, C.C.; Valiante, V.; Schroeckh, V.; Brakhage, A.A. Microbial communication leading to the activation of silent fungal secondary metabolite gene clusters. Front. Microbiol. 2015, 6, 299. [Google Scholar] [CrossRef] [PubMed]
  18. Cheng, Z.S.; Pan, J.H.; Tang, W.C.; Chen, Q.J.; Lin, Y.C. Biodiversity and biotechnological potential of mangrove-associated fungi. J. For. Res. 2009, 20, 63–72. [Google Scholar] [CrossRef]
  19. Debbab, A.; Aly, A.H.; Proksch, P. Bioactive secondary metabolites from endophytes and associated marine derived fungi. Fungal Divers. 2011, 49, 1. [Google Scholar] [CrossRef]
  20. Thatoi, H.; Behera, B.C.; Mishra, R.R. Ecological role and biotechnological potential of mangrove fungi: A review. Mycology 2013, 4, 54–71. [Google Scholar]
  21. Wang, X.; Mao, Z.G.; Song, B.B.; Chen, C.H.; Xiao, W.W.; Hu, B.; Wang, J.W.; Jiang, X.B.; Zhu, Y.H.; Wang, H.J. Advances in the study of the structures and bioactivities of metabolites isolated from mangrove-derived fungi in the South China Sea. Mar. Drugs 2013, 11, 3601–3616. [Google Scholar] [CrossRef] [PubMed]
  22. Wang, K.W.; Wang, S.W.; Wu, B.; Wei, J.G. Bioactive natural compounds from the mangrove endophytic fungi. Mini Rev. Med. Chem. 2014, 14, 370–391. [Google Scholar] [CrossRef] [PubMed]
  23. Huang, H.; Liu, T.; Wu, X.; Guo, J.; Lan, X.; Zhu, Q.; Zheng, X.; Zhang, K. A new antibacterial chromone derivative from mangrove-derived fungus Penicillium aculeatum (No. 9EB). Nat. Prod. Res. 2017, 31, 2593–2598. [Google Scholar] [CrossRef] [PubMed]
  24. Chen, S.; Liu, Y.; Liu, Z.; Cai, R.; Lu, Y.; Huang, X.; She, Z. Isocoumarins and benzofurans from the mangrove endophytic fungus Talaromyces amestolkiae possess α-glucosidase inhibitory and antibacterial activities. RSC Adv. 2016, 6, 26412–26420. [Google Scholar] [CrossRef]
  25. Chen, S.; He, L.; Dongni, C.; Cai, R.; Long, Y.; Lu, Y.; She, Z. Talaramide A, an unusual alkaloid from the mangrove endophytic fungus Talaromyces sp.(HZ-YX1) as inhibitor of mycobacterial PknG. New J. Chem. 2017, 41, 4273–4276. [Google Scholar] [CrossRef]
  26. Frisvad, J.C.; Yilmaz, N.; Thrane, U.; Rasmussen, K.B.; Houbraken, J.; Samson, R.A. Talaromyces atroroseus, a new species efficiently producing industrially relevant red pigments. PLoS ONE 2013, 8, e84102. [Google Scholar] [CrossRef] [PubMed]
  27. Li, H.; Huang, H.; Shao, C.; Huang, H.; Jiang, J.; Zhu, X.; Liu, Y.; Liu, L.; Lu, Y.; Li, M.; et al. Cytotoxic norsesquiterpene peroxides from the endophytic fungus Talaromyces flavus isolated from the mangrove plant Sonneratia apetala. J. Nat. Prod. 2011, 74, 1230–1235. [Google Scholar] [CrossRef] [PubMed]
  28. Sridhar, K.R.; Mangalagangotri, M. Fungal diversity of Pichavaram mangroves, Southeast coast of India. Nat. Sci. 2009, 7, 67–75. [Google Scholar]
  29. Liu, Y.; Xia, G.; Li, H.; Ma, L.; Ding, B.; Lu, Y.; He, L.; Xia, X.; She, Z. Vermistatin derivatives with α-glucosidase inhibitory activity from the mangrove endophytic fungus Penicillium sp. HN29-3B1. Planta Med. 2014, 80, 912–917. [Google Scholar] [CrossRef] [PubMed]
  30. Xing, X.; Guo, S. Fungal endophyte communities in four Rhizophoraceae mangrove species on the south coast of China. Ecol. Res. 2011, 26, 403–409. [Google Scholar] [CrossRef]
  31. Costa, I.P.; Maia, L.C.; Cavalcanti, M.A. Diversity of leaf endophytic fungi in mangrove plants of northeast Brazil. Braz. J. Microbiol. 2012, 43, 1165–1173. [Google Scholar] [CrossRef]
  32. Lin, Z.; Zhu, T.; Fang, Y.; Gu, Q.; Zhu, W. Polyketides from Penicillium sp. JP-1, an endophytic fungus associated with the mangrove plant Aegiceras corniculatum. Phytochemistry 2008, 69, 1273–1278. [Google Scholar] [CrossRef] [PubMed]
  33. Jin, P.F.; Zuo, W.J.; Guo, Z.K.; Mei, W.L.; Dai, H.F. Metabolites from the endophytic fungus Penicillium sp. FJ-1 of Ceriops tagal. Acta Pharm. Sin. 2013, 48, 1688–1691. [Google Scholar]
  34. Zheng, C.; Chen, Y.; Jiang, L.L.; Shi, X.M. Antiproliferative metabolites from the endophytic fungus Penicillium sp. FJ-1 isolated from a mangrove Avicennia marina. Phytochem. Lett. 2014, 10, 272–275. [Google Scholar] [CrossRef]
  35. Liu, J.F.; Chen, W.J.; Xin, B.R.; Lu, J. Metabolites of the endophytic fungus Penicillium sp. FJ-1 of Acanthus ilicifolius. Nat. Prod. Commun. 2014, 9, 799–801. [Google Scholar] [PubMed]
  36. Liu, H.; Chen, S.; Liu, W.; Liu, Y.; Huang, X.; She, Z. Polyketides with immunosuppressive activities from mangrove endophytic fungus Penicillium sp. ZJ-SY2. Mar. Drugs 2016, 14, 217. [Google Scholar] [CrossRef] [PubMed]
  37. Liu, F.; Li, Q.; Yang, H.; Cai, X.L.; Xia, X.K.; Chen, S.P.; Li, M.F.; She, Z.G.; Lin, Y.C. Structure elucidation of three diphenyl ether derivatives from the mangrove endophytic fungus SBE-14 from the South China Sea. Magn. Reson. Chem. 2009, 47, 453–455. [Google Scholar] [CrossRef] [PubMed]
  38. Liu, F.; Cai, X.L.; Yang, H.; Xia, X.K.; Guo, Z.Y.; Yuan, J.; Li, M.F.; She, Z.G.; Lin, Y.C. The bioactive metabolites of the mangrove endophytic fungus Talaromyces sp. ZH-154 isolated from Kandelia candel (L.) Druce. Planta Med. 2010, 76, 185–189. [Google Scholar] [CrossRef] [PubMed]
  39. Cai, R.; Chen, S.; Long, Y.; She, Z. Depsidones from Talaromyces stipitatus SK-4, an endophytic fungus of the mangrove plant Acanthus ilicifolius. Phytochem. Lett. 2017, 20, 196–199. [Google Scholar] [CrossRef]
  40. Sreeta, K.; Dethoup, T.; Singburaudum, N.; Kijjoa, A. Antifungal activities of the crude extracts of endophytic fungi isolated from mangrove plants against phytopathogenic fungi in vitro. In Proceedings of the 52nd Kasetsart University Annual Conference, Agricultural Sciences: Leading Thailand to World Class Standards, Kasetsart, Thailand, 4–7 February 2014; Kasetsart University: Bangkok, Thailand, 2014; Volume 1, pp. 372–379. [Google Scholar]
  41. Liu, Y.; Yang, Q.; Xia, G.; Huang, H.; Li, H.; Ma, L.; Lu, Y.; He, L.; Xia, X.; She, Z. Polyketides with α-glucosidase inhibitory activity from a mangrove endophytic fungus, Penicillium sp. HN29-3B1. J. Nat. Prod. 2015, 78, 1816–1822. [Google Scholar] [CrossRef] [PubMed]
  42. Keller, N.P.; Turner, G.; Bennett, J.W. Fungal secondary metabolism—From biochemistry to genomics. Nat. Rev. Microbiol. 2005, 3, 937–947. [Google Scholar] [CrossRef] [PubMed]
  43. Hussain, H.; Al-Sadi, A.M.; Schulz, B.; Steinert, M.; Khan, A.; Green, I.R.; Ahmed, I. A fruitful decade for fungal polyketides from 2007 to 2016: Antimicrobial activity, chemotaxonomy and chemodiversity. Future Med. Chem. 2017, 9, 1631–1648. [Google Scholar] [CrossRef] [PubMed]
  44. Shukla, V.; Joshi, G.P.; Rawat, M.S.M. Lichens as a potential natural source of bioactive compounds: A review. Phytochem. Rev. 2010, 9, 303–314. [Google Scholar] [CrossRef]
  45. Nicoletti, R.; Manzo, E.; Ciavatta, M.L. Occurence and bioactivities of funicone-related compounds. Int. J. Mol. Sci. 2009, 10, 1430–1444. [Google Scholar] [CrossRef] [PubMed]
  46. Baroni, A.; De Luca, A.; De Filippis, A.; Petrazzuolo, M.; Manente, L.; Nicoletti, R.; Tufano, M.A.; Buommino, E. 3-O-methylfunicone, a metabolite of Penicillium pinophilum, inhibits proliferation of human melanoma cells by causing G2 + M arrest and inducing apoptosis. Cell Prolif. 2009, 42, 541–553. [Google Scholar] [CrossRef] [PubMed]
  47. Buommino, E.; Paoletti, I.; De Filippis, A.; Nicoletti, R.; Ciavatta, M.L.; Menegozzo, S.; Menegozzo, M.; Tufano, M.A. 3-O-Methylfunicone, a metabolite produced by Penicillium pinophilum, modulates ERK1/2 activity, affecting cell motility of human mesothelioma cells. Cell Prolif. 2010, 43, 114–123. [Google Scholar] [CrossRef] [PubMed]
  48. Buommino, E.; Tirino, V.; De Filippis, A.; Silvestri, F.; Nicoletti, R.; Ciavatta, M.L.; Pirozzi, G.; Tufano, M.A. 3-O-methylfunicone, from Penicillium pinophilum, is a selective inhibitor of breast cancer stem cells. Cell Prolif. 2011, 44, 401–409. [Google Scholar] [CrossRef] [PubMed]
  49. Buommino, E.; De Filippis, A.; Nicoletti, R.; Menegozzo, M.; Menegozzo, S.; Ciavatta, M.L.; Rizzo, A.; Brancato, V.; Tufano, M.A.; Donnarumma, G. Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin. Investig. New Drugs 2012, 30, 1343–1351. [Google Scholar] [CrossRef] [PubMed]
  50. Nicoletti, R.; Scognamiglio, M.; Fiorentino, A. Structural and bioactive properties of 3-O-methylfunicone. Mini Rev. Med. Chem. 2014, 14, 1043–1047. [Google Scholar] [CrossRef]
  51. Wu, C.; Zhao, Y.; Chen, R.; Liu, D.; Liu, M.; Proksch, P.; Guo, P.; Lin, W. Phenolic metabolites from mangrove-associated Penicillium pinophilum fungus with lipid-lowering effects. RSC Adv. 2016, 6, 21969–21978. [Google Scholar] [CrossRef]
  52. Masters, K.S.; Bräse, S. Xanthones from fungi, lichens, and bacteria: The natural products and their synthesis. Chem. Rev. 2012, 112, 3717–3776. [Google Scholar] [CrossRef] [PubMed]
  53. Negreiros de Carvalho, P.L.; de Oliveira Silva, E.; Chagas-Paula, D.A.; Hortolan Luiz, J.H.; Ikegaki, M. Importance and implications of the production of phenolic secondary metabolites by endophytic fungi: A mini-review. Mini Rev. Med. Chem. 2016, 16, 259–271. [Google Scholar] [CrossRef] [PubMed]
  54. Shamsuzzaman, H.K. Bioactive benzofuran derivatives: A review. Eur. J. Med. Chem. 2015, 97, 483–504. [Google Scholar]
  55. Saeed, A. Isocoumarins, miraculous natural products blessed with diverse pharmacological activities. Eur. J. Med. Chem. 2016, 116, 290–317. [Google Scholar] [CrossRef] [PubMed]
  56. Mapari, S.A.; Thrane, U.; Meyer, A.S. Fungal polyketide azaphilone pigments as future natural food colorants? Trends Biotechnol. 2010, 28, 300–307. [Google Scholar] [CrossRef] [PubMed]
  57. Osmanova, N.; Schultze, W.; Ayoub, N. Azaphilones: A class of fungal metabolites with diverse biological activities. Phytochem. Rev. 2010, 9, 315–342. [Google Scholar] [CrossRef]
  58. Gao, J.M.; Yang, S.X.; Qin, J.C. Azaphilones: Chemistry and biology. Chem. Rev. 2013, 113, 4755–4811. [Google Scholar] [CrossRef] [PubMed]
  59. Barton, D.H.R.; Sutherland, J.K. The nonadrides. Part I. Introduction and general survey. J. Chem. Soc. 1965, 1769–1772. [Google Scholar] [CrossRef]
  60. Bloomer, J.L.; Moppett, C.E.; Sutherland, J.K. The nonadrides. Part V. Biosynthesis of glauconic acid. J. Chem. Soc. C Org. 1968, 588–591. [Google Scholar] [CrossRef]
  61. Cox, R.E.; Holker, J.S. Biosynthesis of glauconic acid from [2, 3–13 C] succinate. J. Chem. Soc. Chem. Commun. 1976, 15, 583–584. [Google Scholar] [CrossRef]
  62. Zhang, Y.; Han, T.; Ming, Q.; Wu, L.; Rahman, K.; Qin, L. Alkaloids produced by endophytic fungi: A review. Nat. Prod. Commun. 2012, 7, 963–968. [Google Scholar] [PubMed]
  63. West, R.R.; Van Ness, J.; Varming, A.M.; Rassing, B.; Biggs, S.; Gasper, S.; Mckernan, P.A.; Piggott, J. ZG-1494α, a novel platelet-activating factor acetyltransferase inhibitor from Penicilium rubrum, isolation, structure elucidation and biological activity. J. Antibiot. 1996, 49, 967–973. [Google Scholar] [CrossRef] [PubMed]
  64. Higginbotham, S.J.; Arnold, A.E.; Ibañez, A.; Spadafora, C.; Coley, P.D.; Kursar, T.A. Bioactivity of fungal endophytes as a function of endophyte taxonomy and the taxonomy and distribution of their host plants. PLoS ONE 2013, 8, e73192. [Google Scholar] [CrossRef] [PubMed]
  65. El-Elimat, T.; Figueroa, M.; Ehrmann, B.M.; Cech, N.B.; Pearce, C.J.; Oberlies, N.H. High-resolution MS, MS/MS, and UV database of fungal secondary metabolites as a dereplication protocol for bioactive natural products. J. Nat. Prod. 2013, 76, 1709–1716. [Google Scholar] [CrossRef] [PubMed]
  66. Nielsen, K.F.; Larsen, T.O. The importance of mass spectrometric dereplication in fungal secondary metabolite analysis. Front. Microbiol. 2015, 6, 71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Jones, M.B.; Nierman, W.C.; Shan, Y.; Frank, B.C.; Spoering, A.; Ling, L.; Peoples, A.; Zullo, A.; Lewis, K.; Nelson, K.E. Reducing the bottleneck in discovery of novel antibiotics. Microb. Ecol. 2017, 73, 658–667. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. List of mangrove-associated Talaromyces strains gathered from the literature.
Table 1. List of mangrove-associated Talaromyces strains gathered from the literature.
Species/StrainSourceLocationReference
T. aculeatus/9EBKandelia candel (leaf)Yangjiang (Guangdong), China[23]
T. amestolkiae/YX1Kandelia obovata (leaf)Zhanjiang Mangrove Natural Reserve (Guangdong), China[24]
T. amestolkiae/HZ-YX1K. obovata (leaf)Huizhou Mangrove Natural Reserve (Guangdong), China[25]
T. atroroseus/IBT 20955Laguncularia racemosa (root)Paria Bay, Venezuela[26]
T. flavus/CCTCCM2010266Sonneratia apetala (leaf)Hainan, China[27]
T. funiculosusAvicennia officinalis (root) Rhizophora mucronata (root) undetermined species (leaf)Pichavaram (Tamil Nadu), India[28]
T. pinophilus/HN29-3B1Cerbera manghasDong Zhai Gang Mangrove Natural Reserve (Hainan), China[29]
T. pinophilusCeriops tagal (root)Dong Zhai Gang (Hainan), China[30]
T. pinophilusL. racemosa (leaf)Itamaracá Island, Brazil[31]
T. purpurogenus/JP-1Aegiceras corniculatum (bark)Fujian, China[32]
Talaromyces sp./FJ-1 1C. tagal (stem)Haikou (Hainan), China[33]
Talaromyces sp./FJ-1 1Avicennia marinaFujian, China[34]
Talaromyces sp./FJ-1 1Acanthus ilicifoliusHainan, China[35]
Talaromyces sp./ZJ-SY2 1S. apetala (leaf)Zhanjiang Mangrove Natural Reserve (Guangdong), China[36]
Talaromyces sp./SBE-14K. candel (bark)Hong Kong, China[37]
Talaromyces sp./ZH154K. candel (bark)Zhuhai (Guangdong), China[38]
T. stipitatus/SK-4A. ilicifolius (leaf)Shankou Mangrove Natural Reserve (Guangxi), China[39]
T. trachyspermus/KUFA35not specifiedThailand[40]
1 These strains reported as Penicillium sp.
Table
Table 2. Structures and bioactivities of secondary metabolites produced by manglicolous Talaromyces strains. The names of novel compounds are underlined. Compounds marked by an asterisk were previously reported from Talaromyces strains from sources other than mangroves [3,11,12].
Table 2. Structures and bioactivities of secondary metabolites produced by manglicolous Talaromyces strains. The names of novel compounds are underlined. Compounds marked by an asterisk were previously reported from Talaromyces strains from sources other than mangroves [3,11,12].
Compound NameStructureReported BioactivitiesReference
Depsidones, Diphenyl Ether Derivatives
Penicillide * (R = H)
Purpactin A * (=vermixocin B)
(R = CH3CO)		 Marinedrugs 16 00012 i001[39]
Secopenicillide B Marinedrugs 16 00012 i002[39]
Talaromyone A (R = H) Marinedrugs 16 00012 i003Antibacterial: (MIC μg/mL) B. subtilis 12.5 (talaromyone B)[39]
Talaromyone B (R = CH3CO)α-Glucosidase inhibitor (IC50 μM) 48.4 (talaromyone B)
Tenelate A (R = H)
Tenelate B (R = CH2CH3)		 Marinedrugs 16 00012 i004[37]
Tenellic acid A * Marinedrugs 16 00012 i005α-Glucosidase inhibitor (IC50 μM) 99.8[39]
Tenellic acid C Marinedrugs 16 00012 i006[37,39]
Funicones, Vermistatins
3-O-Methylfunicone * Marinedrugs 16 00012 i007[41]
Penicidone D Marinedrugs 16 00012 i008[41]
(±)-Penifupyrone Marinedrugs 16 00012 i009α-Glucosidase inhibitor (IC50 μM) 14.4[41]
Penisimplicissin * (R1 = H, R2 = CH3)
6-Demethylpenisimplicissin (R1 = R2 = H)
5′-Hydroxypenisimplicissin (R1 = OH, R2 = CH3)		 Marinedrugs 16 00012 i010α-Glucosidase inhibitor (IC50 μM) 9.5 (6-demethylpenisimplicissin)[29]
Vermistatin * (R = H) Hydroxyvermistatin * (R = OH) Methoxyvermistatin * (R = OCH3) Marinedrugs 16 00012 i011α-Glucosidase inhibitors (IC50 μM) 29.2, 20.3 1[29]
2′′-Epihydroxydihydrovermistatin Marinedrugs 16 00012 i012α-Glucosidase inhibitor (IC50 μM) 8.0[29]
6-Demethylvermistatin Marinedrugs 16 00012 i013[29]
Anthraquinones
Emodin * Marinedrugs 16 00012 i014Antibacterial: (MIC μg/mL) E. coli 6.25; P. aeruginosa 12.5; S. ventriculi 12.5; S. aureus 12.5[38]
Antifungal: (MIC μg/mL) A. niger 12.5; C. albicans 6.25; F. oxysporum f.sp. cubense 25.0
Cytotoxic: (IC50 μg/mL) KB 12.43; KBv200 15.72
Skyrin * Marinedrugs 16 00012 i015Antibacterial: (MIC μg/mL) E. coli 25.0; P. aeruginosa 12.5; S. ventriculi 25.0; S. aureus 25.0[38]
Antifungal: (MIC μg/mL) A. niger 25.0; C. albicans 12.25
Cytotoxic: (IC50 μg/mL) KB 20.38; KBv200 16.06
Xanthones
Conioxanthone A (R1 = H, R2 = R3 = OH)
8-Hydroxy-6-methyl-9-oxo-9H-xanthene-1-methylcarboxylate (R1 = R2 = R3 = H)
Pinselin (R1 = OH, R2 = R3 = H)
Sydowinin A (R1 = OH, R2 = H, R3 = OH)
Sydowinin B (R1 = R2 = H, R3 = OH)		 Marinedrugs 16 00012 i016Immunosuppressive: (IC50 μg/mL) Con A-Induced 8.2, 25.7, 5.9, 6.5, 19.2 1[36]
Immunosuppressive: (IC50 μg/mL) LPS-Induced 7.5, 26.4, 7.5, 7.1, 20.8 1
Norlichexanthone Marinedrugs 16 00012 i017Antibacterial: (MIC μg/mL) P. aeruginosa 25.0; S. ventriculi 25.0; S. aureus 12.5[38]
Antifungal (MIC μg/mL) A. niger 25.0; C. albicans 6.25; F. oxysporum f.sp. cubense 50.0
Cytotoxic: (IC50 μg/mL) KB 12.43; KBv200 15.72
Peniphenone (R = H) Marinedrugs 16 00012 i018Immunosuppressive: Con A-Induced (IC50 μg/mL) 8.1, 17.5 1[36]
Methylpeniphenone (R = CH3)Immunosuppressive: LPS-Induced (IC50 μg/mL) 9.3, 23.7 1
Remisporine B (R = βH)
Epiremisporine B (R = αH)		 Marinedrugs 16 00012 i019[36]
Secalonic acid A Marinedrugs 16 00012 i020Antibacterial: (MIC μg/mL) E. coli 25.0; P. aeruginosa 12.5; S. ventriculi 12.5; S. aureus 12.5[38]
Antifungal (MIC μg/mL) A. niger 6.25; C. albicans 6.25; F. oxysporum f.sp. cubense 12.5
Cytotoxic: (IC50 μg/mL) KB 0.63; KBv200 1.05
Stemphyperylenol Marinedrugs 16 00012 i021Antibacterial: (MIC μg/mL) P. aeruginosa 12.5; S. ventriculi 3.12; S. aureus 25.0[38]
Antifungal: (MIC μg/mL) A. niger 50.0; C. albicans 6.25
Cytotoxic: (IC50 μg/mL) KB 20.20; KBv200 44.35
Benzophenone Analogs
Arugosin I Marinedrugs 16 00012 i022[32]
Penicillenone Marinedrugs 16 00012 i023Cytotoxic: (IC50 μM) P388 1.38[32]
Phenols, Biphenyls
4-(2′,3′-Dihydroxy-3′-ethyl-butanoxy)-phenethanol Marinedrugs 16 00012 i024Cytotoxic: (IC50 μM) MG-63 35, Tca8113 26[34]
2,4-Dihydroxy-6-methylbenzoic acid (R = COOH)
5-Methylbenzene-1,3-diol (R = H)		 Marinedrugs 16 00012 i025[41]
4′-(S)-(3,5-Dihydroxyphenyl)-4′-hydroxy-6′-methylcyclopent-1′-en-5′-one Marinedrugs 16 00012 i026[41]
6′-Methyl-[1,1′-biphenyl]-3,3′,4′,5-tetraol Marinedrugs 16 00012 i027α-Glucosidase inhibitor (IC50 μM) 2.2[41]
Benzofurans
5-Carboxyphthalide Marinedrugs 16 00012 i028[23]
1-(5-Hydroxy-7-methoxy-benzofuran-3-yl)-ethanone Marinedrugs 16 00012 i029Antibacterial: (MIC μg/mL) B. subtilis 50; E. coli 50; S. aureus 25; S. epidermidis 50[24]
5-Hydroxy-7-methoxy-2-methyl-benzofuran-3-carboxylic acid Marinedrugs 16 00012 i030Antibacterial (MIC μg/mL) B. subtilis 25; E. coli 50; S. aureus 25; S. epidermidis 25[24]
Isocoumarins
Aspergillumarin A * Marinedrugs 16 00012 i031α-Glucosidase inhibitor (IC50 μM) 38.1[24]
Aspergillumarin B * (R1 = R2 = H)
Penicimarin B * (R1 = CH3, R2 = H)
Penicimarin C * (R1 = CH3, R2 = OH)		 Marinedrugs 16 00012 i032α-Glucosidase inhibitors (IC50 μM) 193.1, 431.4, 266.3 1[24]
6,8-Dihydroxy-3,4-dimethyl-isocoumarin (R1 = H, R2 = H, R3 = CH3)
6,8-Dihydroxy-5-methoxy-3-methyl-isochromen-1-one (R1 = H, R2 = CH3, R3 = H)
6-Hydroxy-8-methoxy-3,4-dimethylisocoumarin (R1 = CH3, R2 = H, R3 = CH3)		 Marinedrugs 16 00012 i033α-Glucosidase inhibitor (IC50 μM) 34.4, 89.4, 585.7 1[24]
3-(4,5-Dihydroxy-pentyl)-8-hydroxy-isochroman-1-one Marinedrugs 16 00012 i034α-Glucosidase inhibitor (IC50 μM) 162.5[24]
5,6-Dihydroxy-3-(4-hydroxy-pentyl)-isochroman-1-one Marinedrugs 16 00012 i035α-Glucosidase inhibitor (IC50 μM) 142.1[24]
6-Hydroxy-4-(1-hydroxy-ethyl)-8-methoxy-isocoumarin 2 (R1 = CH3, R2 = H)
Sescandelin (R1 = R2 = H)
5,6,8-Trihydroxy-4-(1-hydroxy-ethyl)-isocoumarin (R1 = H, R2 = OH)		 Marinedrugs 16 00012 i036α-Glucosidase inhibitor (IC50 μM) 537.3[24]
6-Hydroxy-4-hydroxymethyl-8-methoxy-3-methyl-isocoumarin (R = CH3)
Sescandelin B * (R = H)		 Marinedrugs 16 00012 i037α-Glucosidase inhibitors (IC50 μM) 302.6, 17.2 1[24]
Isobutyric acid 5,7-dihydroxy-2-methyl-4-oxo-3,4-dihydro-naphththalen-1-yl methyl ester Marinedrugs 16 00012 i038α-Glucosidase inhibitor (IC50 μM) 140.8[24]
Deoxytalaroflavone Marinedrugs 16 00012 i039Antibacterial (S. aureus)[33]
7-Hydroxy-deoxytalaroflavone Marinedrugs 16 00012 i040Antibacterial (S. aureus, m.r.-S. aureus)[33]
Azaphilones
7-Epiaustdiol (R = H)
8-O-Methylepiaustdiol (R = CH3)		 Marinedrugs 16 00012 i041Antibacterial: (MIC μg/mL) E. coli > 100, 25; P. aeruginosa 6.26, 25.0; S. ventriculi 25.0, 50; S. aureus 12.6, 50.0 1[38]
Antifungal: (MIC μg/mL) A. niger 25.0, 50.0; C. albicans 12.5, 25.0 1
Cytotoxic: (IC50 μg/mL) KB 20.04, 16.37; KBv200 19.32, 37.16 1
Monascorubramine Marinedrugs 16 00012 i042[26]
Monascorubrin Marinedrugs 16 00012 i043[26]
Pinazaphilone A Marinedrugs 16 00012 i044α-Glucosidase inhibitor (IC50 μM) 81.7[41]
Pinazaphilone B (R1 = CH3, R2 = OH)
Sch 1385568 * (R1 = OH, R2 = CH3)		 Marinedrugs 16 00012 i045α-Glucosidase inhibitor (IC50 μM) 28.0[41]
Sequoiamonascin D Marinedrugs 16 00012 i046[32]
Sequoiatone A Marinedrugs 16 00012 i047[32]
Sequoiatone B Marinedrugs 16 00012 i048[32]
Nonadrides
Glauconic acid * Marinedrugs 16 00012 i049[26]
Phenalenone Derivatives
Bacillosporin A * (R = CH3CO)
Bacillosporin B * (R = H)		 Marinedrugs 16 00012 i050α-Glucosidase inhibitors (IC50 μM) 33.55, 95.81 1[23,32]
Bacillosporin C * Marinedrugs 16 00012 i051[32]
9-Demethyl FR-901235 Marinedrugs 16 00012 i052[32]
Chromones
(2′S *)-2-(2′-Hydroxypropyl)-5-methyl-7,8-dihydroxy-chromone Marinedrugs 16 00012 i053Antibacterial (MIC μM) Salmonella 2.0[23]
Cyclohexenones
Leptosphaerone C Marinedrugs 16 00012 i054Cytotoxic: (IC50 μM) A-549 1.45[32]
Flavonoids
(2R,3S)-Pinobanksin-3-cinnamate Marinedrugs 16 00012 i055Neuroprotective[35]
Alkaloids
Talaramide Marinedrugs 16 00012 i056Antimycobacterial: (IC50 μM) PknG kinase inhibitor 55[25]
ZG-1494α * Marinedrugs 16 00012 i057[26]
Terpenes
15-Hydroxy-6α,12-epoxy-7β,10αH,11βH-spiroax-4-ene-12-one Marinedrugs 16 00012 i058Cytotoxic: (IC50 μM) MG-63 55nM, Tca8113 10, WRL-68 58[34]
15-α-Hydroxy-(22E,24R)-ergosta-3,5,8(14),22-tetraen-7-one Marinedrugs 16 00012 i059Cytotoxic: glioma cell lines (IC50 μM) U251 3.2, BT-325 4.1, SHG-44 2.3[35]
Purpuride * Marinedrugs 16 00012 i060[26]
Steperoxide B (=merulin A) (R = H) Marinedrugs 16 00012 i061Toxic to brine shrimp[27]
Talaperoxide A (R = CH3CO)Cytotoxic: (IC50 μM) HeLa 7.97, 13.7; HepG2 6.79, 12.93; MCF-7 4.17, 19.77; MDA-MB-435 1.90, 11.78; PC-3 1.82, 5.70 1
Talaperoxide B Marinedrugs 16 00012 i062Toxic to brine shrimp Cytotoxic: (IC50 μM) HeLa 1.73, HepG2 1.29; MCF-7 1.33; MDA-MB-435 2.78; PC-3 0.89[27]
Talaperoxide C Marinedrugs 16 00012 i063Toxic to brine shrimp Cytotoxic: (IC50 μM) HeLa 12.71; HepG2 15.11; MCF-7 6.63; MDA-MB-435 2.64; PC-3 4.34[27]
Talaperoxide D Marinedrugs 16 00012 i064Toxic to brine shrimpCytotoxic: (IC50 μM) HeLa 1.31; HepG2 0.90; MCF-7 1.92; MDA-MB-435 0.91; PC-3 0.70[27]
1 Data were reported according to the order of compounds; 2 This compound was incorrectly named 5-hydroxy-4-(1-hydroxy-ethyl)-8-methoxy-isocoumarin in the original report.

Share and Cite

MDPI and ACS Style

Nicoletti, R.; Salvatore, M.M.; Andolfi, A. Secondary Metabolites of Mangrove-Associated Strains of Talaromyces. Mar. Drugs 2018, 16, 12. https://doi.org/10.3390/md16010012

AMA Style

Nicoletti R, Salvatore MM, Andolfi A. Secondary Metabolites of Mangrove-Associated Strains of Talaromyces. Marine Drugs. 2018; 16(1):12. https://doi.org/10.3390/md16010012

Chicago/Turabian Style

Nicoletti, Rosario, Maria Michela Salvatore, and Anna Andolfi. 2018. "Secondary Metabolites of Mangrove-Associated Strains of Talaromyces" Marine Drugs 16, no. 1: 12. https://doi.org/10.3390/md16010012

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop